Want to see FR:ALCLS full AI Analyst Report?
ALCLS Stock Chart & Stats
€2.59
<€0.01(0.23%)
At close: 4:00 PM EDT
€2.59
<€0.01(0.23%)
Day’s Range― - ―
52-Week Range€2.03 - €4.84
Previous CloseN/A
Volume109.61K
Average Volume (3M)852.48K
Market Cap
€196.58M
Enterprise Value€205.35
Total Cash (Recent Filing)€166.85M
Total Debt (Recent Filing)€84.57M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 09, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€52.22M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA high gross margin indicates the underlying technology and candidate economics may support attractive contribution margins if development programs reach scale, although current operating expenses still substantially exceed gross profit.
Off-the-Shelf Cell Therapy PlatformAllogeneic, off-the-shelf therapies could offer manufacturing and logistical advantages over individualized treatments. Cellectis’s gene-editing and cell-engineering capabilities provide a platform for developing multiple candidates across oncology.
Cash Generation CapacityPositive operating and free cash flow in 2024 demonstrates that cash generation is possible under favorable conditions. This provides evidence of potential financial flexibility, though recent periods have returned to substantial cash consumption.
Bears Say
Declining RevenueRevenue contraction and volatility make it difficult to establish a dependable growth trajectory. For a clinical-stage company reliant on collaborations and milestone payments, uneven income can complicate planning and delay progress toward scale.
Deep Losses And Cash BurnPersistent operating losses and substantial cash burn indicate that the current revenue base does not support the cost structure. Continued funding needs could limit development flexibility and increase reliance on external capital or partners.
Higher Balance-Sheet LeverageHigher leverage combined with a shrinking equity cushion increases financial risk and reduces flexibility if additional capital is required. Sustained losses may further weaken the balance sheet and raise dependence on financing or strategic transactions.
Cellectis SA News
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €2.03 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €196.58M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 83 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.227 by €0.037.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.18.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.227. Following the earnings report the stock price went down -0.495%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
ALCLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all FR:ALCLS earnings summariesTechnical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―